Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles

References

• Sibai BM. Maternal and uteroplacental hemodynamics for the classification and prediction of preeclampsia. Hypertension 2008;52:805–6
   PubMed Web of Science ®Google Scholar
• Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200–4
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Gotsch F, et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med 2008;21:41–52
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009;30:S38–42
   PubMed Web of Science ®Google Scholar
• Smith GCS, Wear H. The perinatal implications of angiogenic factors. Curr Opin Obstet Gynecol 2009;21:111–16
   PubMed Web of Science ®Google Scholar
• Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 2005;48:372–86
   PubMed Web of Science ®Google Scholar
• Andraweera PH, Dekker G, Roberts CT. The vascular endothelial growth factor family in adverse pregnancy outcomes. Hum Reprod Update 2012;18:436–57
   PubMed Web of Science ®Google Scholar
• Wallner W, Sengenberger R, Strick R, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci 2007;112:51–7
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83
   PubMed Web of Science ®Google Scholar
• Brown MA, Lindheimer MD, de Swiet M, et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX–XIV
   PubMed Web of Science ®Google Scholar
• Arduini D, Rizzo G, Boccolini MR, et al. Functional assessment of uteroplacental and fetal circulations by means of color Doppler ultrasonography. J Ultrasound Med 1990;9:249–53
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 2008;21:25–40
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. [Erratum appears in Nat Med 2006;12:862]. Nat Med 2006;12:642–9
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. [Erratum appears in N Engl J Med 2006;355:1840]. N Engl J Med 2006;355:992–1005
   PubMed Web of Science ®Google Scholar
• Shibata E, Rajakumar A, Powers RW, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90:4895–903
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23
   PubMed Web of Science ®Google Scholar
• Savvidou MD, Yu CK, Harland LC, et al. Maternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol 2006;195:1668–73
   PubMed Web of Science ®Google Scholar
• Stepan H, Kramer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007;92:2831–4
   PubMed Web of Science ®Google Scholar
• Todros T, Sciarrone A, Piccoli E, et al. Umbilical Doppler waveforms and placental villous angiogenesis in pregnancies complicated by fetal growth restriction. Obstet Gynecol 1999;93:499–503
   PubMed Web of Science ®Google Scholar
• Shen BQ, Lee DY, Gerber HP, et al. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 1998;273:29979–85
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Tarca AL, et al. A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. Am J Obstet Gynecol 2010;202:550.e1–10
   PubMed Web of Science ®Google Scholar
• Espinoza J, Chaiworapongsa T, Romero R, et al. Unexplained fetal death: another anti-angiogenic state. J Matern Fetal Neonatal Med 2007;20:495–507
   PubMed Web of Science ®Google Scholar
• Rana S, Schnettler W, Powe C, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013;32:189–201
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Chaiworapongsa T, et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009;22:1021–38
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol 2004;190:1541–7; discussion 1547–50
   PubMed Web of Science ®Google Scholar
• Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013;61:932–42
   PubMed Web of Science ®Google Scholar
• Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996;175:1365–70
   PubMed Web of Science ®Google Scholar
• Bamfo JEAK, Kametas NA, Chambers JB, Nicolaides KH. Maternal cardiac function in normotensive and pre-eclamptic intrauterine growth restriction. Ultrasound Obstet Gynecol 2008;32:682–6
   PubMed Web of Science ®Google Scholar
• Redman CW, Denson KW, Beilin LJ, et al. Factor-VIII consumption in pre-eclampsia. Lancet 1977;2:1249–52
   PubMed Web of Science ®Google Scholar
• Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006;195:40–9
   PubMed Web of Science ®Google Scholar
• Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124:940–50
   PubMed Web of Science ®Google Scholar